López-Karpovitch X, Ulloa-Aguirre A, von Eiff C, Hurtado-Monroy R, Alanis A
Haematology Department, Instituto Nacional de la Nutrición Salvador Zubirán, México.
Acta Haematol. 1992;87(3):148-50. doi: 10.1159/000204742.
The in vivo response to recombinant human granulocyte-monocyte colony-stimulating factor (rHu GM-CSF) in facilitating the reconstitution of granulomonopoiesis was evaluated in a patient with Graves' disease who developed severe aplastic anemia during methimazole therapy. After 10 days of treatment with rHu GM-CSF, the neutrophil and monocyte counts rose to 1.65 x 10(9)/l and 0.41 x 10(9)/l, respectively. However, the patient was still dependent on erythrocyte and platelet transfusions. Two days after rHu GM-CSF withdrawal, the neutrophil count dropped off to 0.41 x 10(9)/l.rHu GM-CSF was reinitiated for 2 days along with glucocorticosteroids. With this combined therapeutic approach, the neutrophil count returned to normal and remained stable, and both Hb and platelet values began to improve. It is concluded that the combination of rHu GM-CSF and glucocorticosteroids can be used as a therapeutic option that may lead to beneficial results in drug-induced aplastic anemia.
在一名格雷夫斯病患者中评估了重组人粒细胞-单核细胞集落刺激因子（rHu GM-CSF）在促进粒单系造血重建方面的体内反应，该患者在甲巯咪唑治疗期间发生了严重再生障碍性贫血。用rHu GM-CSF治疗10天后，中性粒细胞和单核细胞计数分别升至1.65×10⁹/L和0.41×10⁹/L。然而，该患者仍依赖红细胞和血小板输血。停用rHu GM-CSF两天后，中性粒细胞计数降至0.41×10⁹/L。rHu GM-CSF与糖皮质激素一起重新开始使用2天。采用这种联合治疗方法后，中性粒细胞计数恢复正常并保持稳定，血红蛋白和血小板值均开始改善。得出结论，rHu GM-CSF与糖皮质激素联合使用可作为一种治疗选择，可能对药物性再生障碍性贫血产生有益效果。
